Stories of Life With Esophageal Cancer: Roger, Ellen, and Jeff

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid Tumors

Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer

Mirvetuximab Soravtansine Elicits Practice-Changing Outcomes in Frα+ Platinum-Resistant Ovarian Cancer

Erdafitinib Reduces Risk of Death by 36% in FGFR-Altered Urothelial Cancer

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid Tumors

Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer

Mirvetuximab Soravtansine Elicits Practice-Changing Outcomes in Frα+ Platinum-Resistant Ovarian Cancer

Erdafitinib Reduces Risk of Death by 36% in FGFR-Altered Urothelial Cancer

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid Tumors

Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer

Mirvetuximab Soravtansine Elicits Practice-Changing Outcomes in Frα+ Platinum-Resistant Ovarian Cancer

Erdafitinib Reduces Risk of Death by 36% in FGFR-Altered Urothelial Cancer

Related Content

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

Patients with pretreated FGFR2/3-altered metastatic urothelial cancer derived a significant survival benefit with erdafitinib.

Nirogacestat Significantly Reduces Pain Severity in Patients With Desmoid Tumors

Podcast

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

Nirogacestat significantly reduced pain scores for patients with desmoid tumors.

Dostarlimab Maintains HRQOL in 3-Year Follow-Up Of Patients With Early Endometrial Cancer

Podcast

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Mirvetuximab Soravtansine Elicits Practice-Changing Outcomes in Frα+ Platinum-Resistant Ovarian Cancer

An analysis of patient-reported outcomes in the phase 3 RUBY trial supports dostarlimab use in patients with primary advanced or recurrent endometrial cancer.